-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 24th AstraZeneum/Pfizer filed an application for the listing of injection cephalosporins in China, which is expected to be approved for listing in China in the near future.
Cephalosporine (trade name: Zinforo) was approved by the FDA in October 2010 as a fifth-generation antibiotic, clinically primarily used to treat acute bacterial skin/skin structure infections and community-obtained bacterial pneumonia.
, which previously held Zinforo's rights to commercialize globally, has North American and Japanese interests in Allergan and Takeda, respectively.
In August 2016, Pfizer obtained interest in several anti-infector drugs outside the U.S. for $550 million in advances, $175 million in deferred payments and milestone payments of up to $250 million, $600 million in sales-related payments and subsequent sales sharing.
.
